HIGHLIGHTS
SUMMARY
Platinum compounds are the most widely used chemotherapy agents for cancer worldwide, but are also known for their serious side effects of ototoxicity. Previous GWASs were mainly conducted in European populations of pediatric patients and those with certain cancer types, only focusing on the risk of hearing loss induced by cisplatin or radiotherapy alone. Patients reporting the event of hearing loss in outpatient clinic follow-up records documented by physicians were defined as cases with hearing loss, whereas those without reported hearing loss were classified as the non-hearing loss group. Baseline gene_expression data . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.